Medical Marijuana Education for Medical Students by McGuire, Patrick
University of Massachusetts Medical School 
eScholarship@UMMS 
Capstone Presentations School of Medicine 
2017-03-06 
Medical Marijuana Education for Medical Students 
Patrick McGuire 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/capstones 
 Part of the Alternative and Complementary Medicine Commons, Medical Education Commons, Other 
Pharmacy and Pharmaceutical Sciences Commons, and the Pharmaceutical Preparations Commons 
Repository Citation 
McGuire P. (2017). Medical Marijuana Education for Medical Students. Capstone Presentations. 
https://doi.org/10.13028/s9gy-md48. Retrieved from https://escholarship.umassmed.edu/capstones/5 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Capstone 
Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Medical Marijuana Education for Medical Students 
 
Patrick McGuire 
Capstone Advisor: Dr. Jeff Baxter 
 
Abstract: 
 
As the nationwide discourse on medical marijuana evolves, with 28 out of 50 states 
approving its use, University of Massachusetts Medical School graduates will need to be 
prepared to discuss medical marijuana (MMJ) with their patients. There is currently no 
formal medical school education on MMJ. This project set out to understand the 
curriculum gap and provide a learning session to interested students. The presentation 
was created using research done by the author during the first three years of medical 
school, including visits to private MMJ clinics. Utilizing a pre/post-session online 
assessment of a group of twenty-six students, we found that student knowledge about 
Massachusetts’ MMJ law improved by 29%, following a ninety-minute session. In 
addition, self-assessed confidence in negotiating clinical scenarios involving marijuana 
improved by 34%. These improvements were statistically significant, with p-values of 
0.0033 and 9.5x10-16 respectively. These findings support the formal addition of a sixty- 
to ninety-minute session focusing on MMJ to the UMMS curriculum.  
 
Introduction: 
 
Medical marijuana gained popularity in the United States beginning in 1996, when 
California approved its use for conditions including glaucoma, persistent muscle spasms, 
and chronic pain. Since that time, twenty-eight states and Washington, DC have voted to 
permit the medical use of marijuana.1 Massachusetts’s voters approved a medical 
marijuana law in 2012, enabling citizens to use marijuana for any one of the following 
“debilitating medical conditions”: Cancer, glaucoma, HIV/AIDS, hepatitis C, 
amyotrophic lateral sclerosis (ALS), Crohn's disease, Parkinson's disease, multiple 
sclerosis or “other conditions as determined in writing by a qualifying patient's 
physician.”2 At that time, the state’s Department of Public Health (DPH) began the 
process of issuing licenses for up to thirty-five medical marijuana dispensaries. Although 
it took several years for the DPH to streamline this dispensary licensing process, 
physicians began certifying patients for the use of medical marijuana immediately. Since 
2012, physicians have certified over 38,000 patients in the use of medical marijuana 
(MMJ).3 As of November 2016, the DPH has licensed dispensaries in eight cities and 
towns: Salem, Ayer, Quincy, Brockton, Brookline, Boston, Lowell and Northampton.  
 
In addition to extensive acceptance of MMJ, our nation is experiencing a relaxation in its 
attitude towards cannabis in general. Most recently, California, Massachusetts, and 
Nevada approved the recreational use of marijuana in November 2016, making seven 
total states and Washington, DC that now permit recreational marijuana.4 These results 
join the introduction of the federal CARERS Act in March of 2015, co-sponsored by 
New Jersey Democrat Cory Booker, New York Democrat Kristen Gillibrand, and 
Kentucky Republican Paul Rand. If passed, this law would make sweeping alterations to 
federal marijuana regulations, including banking changes that would prevent both 
medical and recreational marijuana from being cash-only businesses.5,6  
 
Despite this loosening in America’s restrictions on marijuana use and the nationwide 
prevalence of MMJ, the medical community at large has yet to reach a consensus on the 
appropriate medical uses of marijuana. The FDA has approved two cannabinoid 
medications – nabilone and dronabinol – for the treatment of nausea and vomiting 
associated with chemotherapy and cachexia associated with AIDS, respectively. 
Cannabis itself, though, remains a Schedule I substance according to the DEA, meaning it 
has “no currently accepted medical use.”7 The record of randomized trials demonstrates 
the efficacy of MMJ for certain indications approved by Massachusetts’ 2012 law, but 
not others. The most recent analyses of randomized clinical trials do not support the use 
of MMJ for symptoms related to Parkinson’s disease, Crohn’s disease, or ALS.8 Multiple 
studies have shown evidence supporting the efficacy of MMJ in chronic pain and 
neuropathic pain9, but these are not named as approved conditions in the 2012 law and 
would fall under the “other conditions as determined in writing by a qualifying patient's 
physician” criterion.  
 
Much of the debate surrounding MMJ is limited by the lack of high-quality research into 
the drug. The DEA’s designation as a Schedule I substance makes research into MMJ 
more cumbersome than with substances such as cocaine, methamphetamine, and 
fentanyl, which are designated as Schedule II.7 Additionally, cannabis is a source of over 
sixty-six distinct cannabinoids – compounds with binding activity at one of the two 
cannabinoid receptors.10 Among these cannabinoids, Δ9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) are the best studied, and it is believed THC is responsible for 
euphoria and possibly psychosis, while CBD is responsible for antianxiety effects.8 There 
is still a great deal to be learned about the physiologic effects of marijuana, including 
strains with highly variable concentrations of THC and CBD, despite the fact that it is 
already approved for medical use in over half of American states. According to the 
National Institute on Drug Abuse, the average THC concentration in recreational MJ rose 
to nearly 12% in 2012, from below 4% in 1995.11 Meanwhile, in November 2016, one 
Massachusetts dispensary’s website listed a strain of MMJ with a THC concentration of 
24.6% along with one “shatter” concentrate with 85.6% THC.12 In August 2016, the DEA 
signaled a shift in the future of MMJ research by announcing it would expand the number 
of DEA-registered “marijuana manufacturers” to meet the increasing demand in quantity 
and diversity of MMJ for FDA-approved research.13 Notwithstanding potential future 
improvements in MMJ research, the current lack of standardized dosages, concentrations, 
or a purification processes – as is the standard in traditionally FDA-approved medications 
– complicates research into MMJ.   
 
Graduates of the University of Massachusetts Medical School (UMMS) will be entering a 
life of practice in which they will face questions from patients regarding MMJ; 
Massachusetts’ 2012 law requires physician certification for MMJ use. However, there is 
no current place in the medical school curriculum exploring the legal issues, evidence, or 
clinical considerations for MMJ. This project set out to understand medical student 
attitudes toward MMJ and prepare medical students for practice in a world where MMJ is 
commonplace with a learning module on the medical use of marijuana. Specifically, we 
wondered if a sixty- to ninety-minute learning session could improve students’ 
knowledge level regarding Massachusetts’s law and randomized-controlled evidence 
(RCT) covering MMJ, as well as students’ confidence in approaching clinical MMJ 
scenarios. Twenty-six students participated in an interactive session focusing on the 
current legal status of marijuana, the evidence surrounding the medical use of marijuana, 
and the first-hand experience of physicians and patients.  
 
Methods: 
 
The learning session took place in November 2016 with students participating in 
UMMS’s student-run Substance Abuse Elective; students received credit toward their 
completion of the elective for participation in the session. All medical students were 
made aware of the learning session through a school-wide email and within a weekly 
bulletin organized by the Student Body Committee. Substance Abuse Elective 
participants were also independently notified by the elective’s leadership. Respondents to 
these communications were grouped into an email list and sent a reminder to attend the 
session one day prior to the event.  
 
Evaluation of the session was done through the use of anonymous pre/post-assessments 
completed via an online Google Form submission (Figure 2). All participants agreed to 
complete this anonymous assessment prior to participation in the learning session. 
Participating students were provided a link to the survey immediately before beginning 
the didactic portion of the session. Students were again provided with this link following 
the session. Because not all students were able to stay to complete the post-survey, 
participants were sent an email one day after the session asking them to complete the 
post-survey if they had not yet done so.  
 
The assessment was presented in an identical format both before and after the session. 
Students did not have access to their previous answers when completing the post-survey. 
We chose to assess the session by determining student changes in two broad domains: 
factual knowledge of MMJ medical evidence and law, as well as self-assessed confidence 
and attitude towards MMJ. The goals of the first domain were to understand students’ 
baseline level of knowledge about MMJ and to test if this one-time learning session was 
able to improve student knowledge. Similarly, the goals of the second domain were to 
understand students’ baseline levels of self-assessed confidence and attitude towards 
MMJ, as well as how these parameters changed after the session. We chose to use a 
Likert scale of 1-5 to assess confidence and attitude because it is a widely used method of 
gathering student feedback in medical education, and is a method wherein the pre/post 
data may be compared using a parametric test such as two-tailed t-test analysis .14 The 
specific questions asked in this section were created together with advisor Jeffrey Baxter 
based on prior experiences in medical education. 
 
In the first part of the assessment, students were asked to respond to two prompts 
regarding evidence for and laws about MMJ use with a choice of true or false for twelve 
different medical conditions. Six of the listed indications (multiple sclerosis, Parkinson 
disease, glaucoma, cancer, hepatitis C, and HIV/AIDS) can make patients eligible for 
MMJ in Massachusetts and the other six indications (Alzheimer disease, epilepsy, 
Tourette syndrome, PTSD, severe chronic pain, and terminal illness with life expectancy 
less than one year) are approved indications for MMJ in other states. As discussed in the 
Introduction, the following conditions were considered to have RCT evidence supporting 
treatment with MMJ and presented as such: multiple sclerosis, epilepsy, cancer, severe 
chronic pain, and HIV/AIDS. Thus, there were six options with a correct answer of “true” 
in response to the prompt, “A debilitating form of this condition makes a patient eligible 
for medical marijuana according to Massachusetts' 2012 law,” and there were five 
options with a correct answer of “true” in response to the prompt, “There is randomized-
controlled trial evidence supporting medical marijuana use for this condition.” 
 
Answers to Question 3 of Figure 2 were analyzed by calculating the percentage of correct 
responses for each of the twelve medical conditions in the RCT evidence and MA state 
law columns for the pre/post-assessment responses. The mean percentages of correct 
responses for the pre/post-assessments were compared using a two-tailed t-test analysis 
with an alpha value of 0.05.  
 
In the second part of the assessment, students used a Likert rating scale to evaluate their 
personal confidence in clinical and legal matters surrounding MMJ, as well as their 
personal attitudes toward MMJ. On these scales, 1 indicated strong disagreement and 5 
indicated strong agreement with statements beginning with the phrases, “I am 
confident…”, “I support…”, or “I believe…”. 
 
These data were statistically analyzed by pooling data from two groups of questions 
assessing self-confidence. The pre and post values for parts a, b, and c of Question 4 in 
Figure 3 were pooled and collectively compared using a two-tailed t-test analysis with an 
alpha value of 0.05. All of these questions focused on self-confidence managing clinical 
scenarios involving MMJ. Similarly, parts d and e of Question 4 in Figure 3 were pooled 
and collectively compared. Both of these questions focus on self-confidence in 
understanding the legal status of MMJ. This method of pooling multiple Likert-scale 
questions to create a larger sample size is supported by Sullivan and Artino in assessing 
topics such as self-confidence.14 The mean results from the final three questions were not 
pooled and the two-tailed t-test analysis was conducted on the mean response to each 
individual question. 
 
Results: 
 
Fifty-six students replied to the initial round of communication stating intent to attend the 
learning session and consent to complete the pre/post-assessments. Ultimately, twenty-six 
medical students completed the pre-session survey. This group consisted of seventeen 
members of the class of 2020, seven members of the class of 2019, and two members of 
the class of 2017. Fifteen students completed the post-session survey, or 58% of the 
initial participants. Post-session follow-up was solicited as mentioned in the Methods 
section.  
 
Figure 3 contains columns showing the percentage of correct responses to the RCT and 
MA state law questions, both before and after the session. For analyzing RCT evidence, 
the average correct response rate across all twelve diseases was 58% prior to the learning 
session. After the session, overall average correct response rate rose to 65% in the post-
session assessments. This increase did not represent a statistically significant change.  
The data regarding knowledge of MA state law, also presented in Figure 3, supported a 
statistically significant improvement as a result of the learning session. Prior to the 
session, mean correct response rate across the 12 diseases was 48%. After the session, 
mean correct response rate rose to 77%. The p-value for this change was 0.0033. Thus, 
the learning session improved students’ ability to identify the conditions for which MMJ 
is approved by Massachusetts state law. 
 
Figure 4 contains the data showing mean strength of agreement on Likert scales with the 
statements presented in the second portion of the pre/post-survey. In these scales, 1 
represented strong disagreement and 5 represented strong agreement. The statistical 
analysis of pooled responses to statements a, b, and c support a statistically significant 
increase in mean self-confidence, with the mean rising from 1.9 to 3.6. Participant self-
confidence in knowledge about the legal status of MMJ also increased from a mean of 1.6 
to 3.6. This result was statistically significant, with an extremely small p-value of 1.8x10-
16. Together, these results indicate student self-confidence in matters related to MMJ truly 
did increase as a result of the learning session. 
 
For the final three statements using the Likert scale, we found increases in level of 
support for MMJ, support for inclusion of MMJ material in the UMMS curriculum, and 
plans to include MMJ in future practice. These changes from before to after the session 
were not statistically significant. Of note, these questions had much smaller sample sizes 
because they were not grouped together for analysis. This means larger changes in the 
means would be needed for the results to be statistically significant. 
 
Discussion: 
 
The results of this study support the inclusion of a brief, formal MMJ curriculum in the 
general UMMS curriculum. We have documented UMMS students’ desire to learn more 
about the medical role of marijuana and shown there is a gap in students’ current 
knowledge. Not only are students not aware of the exact laws governing MMJ, they are 
not confident in their ability to counsel patients regarding the health risks and benefits of 
marijuana. This is at a time when Massachusetts’ amount of MMJ certifications grows 
monthly and voters have approved recreational marijuana. By participating in this 
learning session, student factual knowledge and self-confidence both improved. This 
improvement was despite an audio/visual difficulty that prevented showing videos 
summarizing the biological effects of cannabis and evidence regarding its medical use.  
 
This study faced several limitations typical of an informal, survey-driven curriculum 
inquiry. There is an overall small sample size that may have limited our ability to find 
significant changes in the pre/post data. Selection bias also likely played a role 
throughout the recruitment of students to attend the learning session. Attendance was 
voluntary, and although most students received credit as substance-abuse elective 
participants, participation in that elective is itself voluntary and subject to self-selection. 
Together, these points mean that session attendees were not a random sample of medical 
students. These limitations are predictable challenges that arise from an attempt to 
evaluate the UMMS curriculum as was done in this study.  
 
There are numerous options available to UMMS for how to use the findings presented in 
this study. The simplest follow-up would be a required survey of all medical students and 
faculty. This survey would evaluate openness to inclusion of MMJ in the formal 
curriculum and ideas regarding where it may fit best. Recent curriculum changes to 
address the opioid crisis in Massachusetts raise the question of a need for more 
comprehensive mandated addiction curriculum in general.15 Such a program could be 
added in an integrated format or modeled after the currently existing Interstitial Days. In 
either case, this would be an excellent venue for including a discussion of MMJ, in 
particular due to intriguing findings negatively correlating state MMJ use with opioid 
overdose deaths.16 Another option for implementing these findings would be creation of a 
video series for medical students similar to those created by the University of 
Washington Alcohol and Drug Abuse Institute.17 These videos provide education on the 
use of cannabis to treat chronic pain, are freely available online, and can be used to obtain 
Continuing Medical Education (CME) credits. The Massachusetts Medical Society 
(MMS) also provides recordings of lectures focused on MMJ via its online CME 
system.18 These videos are freely available to medical students with MMS membership.  
 
By formally including MMJ in its curriculum, UMMS would be seizing an opportunity to 
ensure that scientific evidence is well represented in the public discourse on marijuana. 
The history of state-by-state approval of medical marijuana in the absence of medical 
consensus on its proper use has created confusion over the facts of marijuana nationwide. 
UMMS has a responsibility to clarify marijuana’s medical status for its students, and by 
extension the broader public. More importantly, UMMS has an opportunity to shape the 
future of MMJ research by exposing its future graduates to an area of medicine that is 
certain to experience significant changes in the coming years. In keeping with UMMS’ 
strong tradition of student-informed curriculum changes, another student’s Capstone 
Project would be an excellent method of introducing this curriculum addition. 
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Appendix: 
Figure 1: This can be found in the accompanying “MMJ Presentation.pdf” file. 
References are documented at the bottom of each slide and compiled on slide 46. The 
presentation is structured around a clinical case of a patient seeking certification for 
MMJ. The major sections are: the biological of marijuana, the legal status of marijuana in 
both Massachusetts and America, a review of the medical evidence on marijuana, and 
important clinical considerations including risks of marijuana use. 
 Figure 2: The following questions were asked via an online Google Form, which can be 
found at this link: https://goo.gl/forms/UnpkFPWgVaiR91s22  
 
Pre/Post Session Assessment 
 
1. Please circle PRE or POST based on when you completed this assessment. 
 
2. Please circle your class year:      2017      2018      2019      2020 
 
3. Please complete the following table. Circle either true or false in both categories:  
evidence for medical marijuana and approved indication by Massachusetts’ 2012 law. 
 
Condition There is randomized-
controlled trial evidence 
supporting medical 
marijuana use for this 
condition: 
A debilitating form 
of this condition 
makes a patient 
eligible for medical 
marijuana according 
to Massachusetts' 
2012 law: 
Multiple Sclerosis True  False True  False 
Parkinson Disease True False True False 
Alzheimer Disease True False True False 
Epilepsy True False True False 
Tourette Syndrome True False True False 
Post-traumatic Stress Disorder True False True False 
Glaucoma True False True False 
Cancer True False True False 
Hepatitis C True False True False 
Severe chronic pain True False True False 
HIV/AIDS True False True False 
Terminal illness with life expectancy 
below 1 year 
True False True False 
 
 
4.  Please respond to the following statements about medical marijuana (MMJ) by 
indicating how strongly you agree with an “X” in the corresponding box: 
 
 
a. I am confident in my ability to identify indications for MMJ in a clinical setting. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
b. I am confident in my ability to identify contraindications for MMJ in a clinical setting. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
c.  I am confident in my ability to counsel a patient on the benefits and drawbacks of 
MMJ. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
d. I am confident in my ability to counsel a patient on the differences between federal law 
and Massachusetts’ state law regarding MMJ use.  
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
e. I am confident I have an understanding of how to navigate the system for certifying a 
patient for MMJ in Massachusetts. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
f. I support the use of MMJ. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
g. I plan to include MMJ in my future medical practice. 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
  
h. I have had clinical or academic exposure to MMJ during medical school.  
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
i. I believe the UMMS curriculum should include more material focusing on MMJ 
Disagree 
strongly 
Disagree 
somewhat 
Neutral Agree 
somewhat 
Agree strongly 
     
 
 
Figure 3: This table shows the percentage of correct responses, in decimal form, for each 
of the conditions assessed in Question 3 of Figure 2, both before and after the session. 
The p-values were obtained using a two-tailed t-test analysis with an alpha value of 0.05. 
 Randomized-controlled 
trial evidence supporting 
effectiveness of medical 
marijuana 
Approved in 
Massachusetts by 2012 
law 
 Pre-
assessment 
Correct 
Percentage 
(n=26) 
Post-
assessment 
Correct 
Percentage 
(n=15) 
Pre-
assessment 
Correct 
Percentage 
(n=26) 
Post-
assessment 
Correct 
Percentage 
(n=15) 
Multiple Sclerosis 0.46 0.60 0.62  0.8 
Hepatitis C 0.85 0.47 0.35 0.93 
Parkinson Disease 0.61 0.66 0.62 1.0 
Alzheimer Disease 0.81 0.73 0.62 0.67 
Cancer 0.69 0.47 0.88 1.0 
Glaucoma 0.53 0.60 0.69 1.0 
Post-traumatic Stress Disorder 0.35 0.87 0.27 0.80 
Tourette Syndrome 0.50 0.87 0.54 0.73 
Epilepsy 0.69 0.53 0.23 0.47 
Terminal illness with life 
expectancy below 1 year 
0.38 0.80 0.23 0.53 
HIV/AIDS 0.31 0.60 0.5 0.93 
Severe chronic pain 0.77 0.60 0.19 0.40 
Mean Correct Percentage 0.58 0.65 0.48 0.77 
Standard Deviation 0.18 0.14 0.22 0.21 
Variance 0.034 0.020 0.049 0.046 
p-value 0.30 0.0033* 
* Indicates statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: This table shows the mean numerical response (scale of 1-5) for each of the 
questions asked in Question 4 of Figure 2, along with the statistical analysis using two-
tailed t-test analysis with an alpha value of 0.05 for two pooled groups of questions.  
 
 Mean strength of 
agreement:  
Pre-assessment 
(n=26) 
Mean strength of 
agreement:  
Post-assessment 
(n=15) 
p-value of Mean 
Comparison  
I am confident in my 
ability to identify 
indications for MMJ in a 
clinical setting. 
 
1.8 3.7 
9.5x10-16* 
I am confident in my 
ability to identify 
contraindications for 
MMJ in a clinical 
setting. 
 
1.8 3.6 
I am confident in my 
ability to counsel a 
patient on the benefits 
and drawbacks of MMJ. 
 
2.1 3.4 
Pooled Mean 1.9 3.6  
Pooled SD 1.0 1.0 
Pooled Variance 0.90 0.80 
I am confident in my 
ability to counsel a 
patient on the 
differences between 
federal law and 
Massachusetts’ state law 
regarding MMJ use.  
 
1.7 3.8 
1.8x10-16* 
I am confident I have an 
understanding of how to 
navigate the system for 
certifying a patient for 
MMJ in Massachusetts. 
 
1.4 3.5 
Pooled Mean 1.6 3.6  
Pooled SD 0.78 0.81 
Pooled Variance 0.60 0.65 
I support the use of 
MMJ. 
 
3.3 3.9 0.13 
I plan to include MMJ in 
my future medical 
practice. 
 
2.9 3.4 0.086 
* Indicates statistical significance. 
 
 
I believe the UMMS 
curriculum should 
include more material 
focusing on MMJ. 
 
3.4 3.7 0.34 
I have had clinical or 
academic exposure to 
MMJ during medical 
school.  
 
1.4 Not recorded  
